> Join the CordenPharma Team at #CPHIMilan - Booth 24C2. After a lively first day of engaging discussions with new and existing customers, we are excited for Day 2! We are the CDMO partner you need for safe and reliable development and manufacturing of high quality APIs, Drug Products, and Lipid Excipients across our six Technology Platforms - Peptides, Lipids, Injectables, Oligonucleotides, Highly Potent & Oncology and Small Molecules - to support your complex pharmaceutical modalities. #CPHIMilan #CPHI #CordenPharma #cdmo #peptides #lipids #injectables #hpapis #osd #SFC #mRNA #lnps #oligos #smallmolecules #pharmaceuticals #healthcare #pharmamanufacturing
Corden Pharma - A Full-Service CDMO
Arzneimittelherstellung
Basel, BS 36.917 Follower:innen
The partner you need.
Info
CordenPharma is your full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Lipid Excipients, Drug Products and Packaging. Through a network of cGMP facilities across Europe and the US organized under six technology platforms – Peptides, Lipids & Carbohydrates, Oligonucleotides, Injectables, Highly Potent & Oncology, Small Molecules - CordenPharma experts translate complex ideas, processes and projects at any stage of development into high-value pharmaceutical products. Visit to learn more > cordenpharma.com
- Website
-
https://www.cordenpharma.com
Externer Link zu Corden Pharma - A Full-Service CDMO
- Branche
- Arzneimittelherstellung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Basel, BS
- Art
- Privatunternehmen
- Gegründet
- 2006
- Spezialgebiete
- Contract Development & Manufacturing Organization (CDMO), Sterile Injectable Drug Products, Aseptic Fill & Finish, Oligonucleotides, Lipid Excipients, LNP Formulation, Peptides, LNP Formulation, Highly Potent APIs & Drug Products und Small Molecule Drug Dosage Forms
Orte
Beschäftigte von Corden Pharma - A Full-Service CDMO
Updates
-
World Mental Health Day: "Let's Take Time to Talk" As part of our ongoing commitment to fostering a supportive and psychologically safe workplace, we successfully held our special initiative for World Mental Health Day on October 10th. On that day, all HR offices across our sites were open for an open-door session, providing employees with the opportunity to speak up and express themselves. Whether employees felt stressed, overwhelmed, or just needed someone to listen, our HR team was there to offer a safe and confidential space for open conversations. This initiative, titled "Let's Take Time to Talk," aimed to create an environment where everyone felt supported, valued, and able to openly share any challenges they might facing. We believe mental well-being is as important as physical health, and we are committed to helping every employee succeed personally and professionally. Thank you to everyone who participated and helped us to continue to shape our working culture with a supportive environment Let’s continue taking time to talk and support one another. #worldmentalhealthday #mentalhealthmatters #employeewellbeing
-
> Article: WACKER and CordenPharma Well Prepared to Tackle New Pandemics - European Biotechnology - Life Science and Industry Magazine (EBM) (Autumn Edition 2024) After being commissioned by the German government in 2022 to prepare their mRNA vaccine production lines for a new pandemic, the consortium formed between WACKER & CordenPharma officially entered the pandemic readiness state as of 1 June 2024, to produce 80 million vaccine doses within a short time, if needed. . Upon the success of achieving this herculean task of building up capacity within an aggressive two-year timeline, both companies share insights in the article into how they addressed these challenges with the expertise and flexibility acquired over many years as leading CDMOs in the mRNA space. CordenPharma brings in-depth expertise in lipids and Lipid NanoParticles (LNPs) and has many years of experience in terminal and aseptic filling. Wacker Biotech has become a specialist in therapeutic proteins, living biotherapeutic products, plasmid DNA and conventional vaccines based on microbial systems. Both companies jointly take on the vaccine’s complete production, from the bioengineering of the mRNA, starting out from plasmid DNA, through to formulation with LNPs and the sterile filling of the final vaccine. CordenPharma’s Global Project Manager Dr. Alexander Radspieler commented: “The next stage involves our various lipids, as the vaccine is formulated in Halle, too. This is almost the last process stage, in which the mRNA is combined with lipids to form Lipid NanoParticles, or LNPs, and packed into a lipid envelope that protects the sensitive vaccine on its way into the muscle cells at the injection point. But first, the frozen vaccine is sent to our sterile filling center in Caponago, northern Italy, where the vaccine is put in prefilled syringes or vials.” As part of measures to combat pandemics, CordenPharma launched two major expansion projects. In one project, the size of the lipid production area was increased to make it possible to produce the necessary quantities. This project also involved investing in Supercritical Fluid Chromatography (SFC), which is an environmentally compatible purification strategy for lipids. In the other project, CordenPharma extended its existing sterile filling capacity so that it would be able to supply clinics, vaccination centers and doctor’s surgeries with the necessary vaccine doses. Read full article online: https://lnkd.in/ehhMzqEc #CordenPharma #Wacker #CDMO #mrna #vaccines #pharmaceuticals #lipids #lnps #injectables #pharmamanufacturing #Germany #sfc #dna #EuropeanBiotechnology #biotech #publichealth #pandemicpreparedness
-
Will we see you in Salt Lake City? #PharmSci360 is only a few weeks away! Our team will be at booth #1502 to explain you how we deliver tailored end-to-end solutions spanning your supply chain at all stages, from drug development to commercialization. Through seamlessly integrated technologies and services across our expert global network, we work alongside you to understand and anticipate your project needs, streamline your process, and drive time and cost efficiencies. Contact us to schedule a meeting in advance: https://lnkd.in/e79WsNiq We look forward to meeting you at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci 360! #cordenpharma #cdmo #pharmaceuticals #pharma #pharmaindustry #drugdevelopment
-
Register for our upcoming webinar on October 30th: https://lnkd.in/ebN3cbgC... Michael Stager, Senior Development Engineer, will discuss the efforts made by industry experts towards greener and cleaner solid-phase peptide synthesis (SPPS) methods and outline the importance of PAT technology in SPPS. Join the webinar to learn more about: - How can Raman spectroscopy be used as a PAT tool for industrial SPPS processes - The advantages of Raman spectroscopy over other PAT tools - Major milestones and challenges for this technology, as well as the industry-wide impacts of adopting a PAT-based approach in pharmaceutical manufacturing #cordenpharma #cdmo #webinar #peptides #spps #flowchemistry #peptidesynthesis #pharma #pharmaceuticals #pharmaindustry
🔬 Join our upcoming webinar on "Raman Spectroscopy and Process Analytical Technology: Improving SPPS in Pharmaceutical Manufacturing" with Corden Pharma - A Full-Service CDMO! Discover how CordenPharma's PAT team uses Raman #spectroscopy to revolutionize solid-phase peptide synthesis (SPPS) for greener, cleaner #manufacturing. 🌱💊 🗓️ October 30 ⏰ 11:00 AM US/Eastern 🔗 Register now: https://ow.ly/9Gur50Tv0fk
-
> CordenPharma Liestal (Switzerland) inaugurates newly-constructed development and GMP purification areas along with two small-scale GMP manufacturing suites to expand our lipid and small molecule product offerings. The newly established Centre of Excellence for Solid State and Crystallization Development is already fully operational. On 25 September, CordenPharma Liestal (CH) Managing Director Dr. Thomas Müller and the site team was joined by CEO Dr. Michael Quirmbach to inaugurate expansions of the Liestal facility production, lab and office space areas with a ribbon-cutting ceremony. Following presentations by leadership, the group gathered for a lively celebratory lunch. After initiating our largest multi-year strategic investment of 11.3 million Swiss Francs into the Liestal facility in 2022, this inauguration celebrates the latest phase of the project, which includes completed expansion of capabilities in small-scale GMP manufacturing and purification capacity, including our highly-efficient and sustainable Supercritical Fluid Chromatography (SFC) technology. The beauty and benefit of SFC for our customers is that it uses mostly CO2 instead of organic solvents, is a much faster process, and allows for the recycling of over 95% of the eluent directly in the running manufacturing process. After receiving a renewed RHI / Swissmedic Operational Permit for Production of APIs and the GMP License in August 2024, the latest expansions in the Liestal facility will start GMP manufacturing in October 2024. Alongside this Liestal expansion and our drug product facility in Ettingen, both of which are close to Basel, we recently announced expansion plans for constructing a new greenfield facility for peptide manufacturing near the Basel area as well, making the Canton of Basel, Switzerland an exciting epicenter of scientific excellence for CordenPharma in supporting innovators with the complex modalities needed for their life-saving medications. 👩🔬 🚀 #CordenPharma #Baseljobs #lipids #smallmolecules #technology #innovation #pharmaceuticals #pharmamanufacturing #sfc #purification #esg #hiring #sustainability #greentechnology #solidstate #cdmo #Switzerland
-
> CordenPharma Fribourg (CH) was honored to welcome BioAlps - Swiss Health Valley representative members to share our mutual passion, know-how, expertise, needs and challenges facing life science innovation in the Fribourg Canton of Switzerland. On 24 September, CordenPharma Fribourg facility Managing Director Yvan Liard was joined by CordenPharma Key Account Associate Director Julien Rousset and and the Fribourg site team to welcome Swiss Health Valley member representatives to hear presentations on life science innovations and developments and learn more about the CDMO contributions of CordenPharma. The engaging speakers included Magali Bischof, Secretary General of BioAlps, Jerry Krattiger Managing Director of Fribourg Development Agency at Etat de Fribourg - Staat Freiburg, and Elise Gortchacow-Bretton, Innovation Consultant at Alliance-Innovation, followed by comments from Yvan Liard and Julien Rousset. Next representatives were given a tour of the Fribourg site, which featured our drug product production areas including tablet manufacturing, packaging, labs and logistics. The event concluded with a networking reception and lively exchange of ideas. We are grateful for the support and collaboration of BioAlps - Swiss Health Valley and Fribourg Development Agency FDA, to whom we address our warmest thanks. We thank all participants for your presence and commitment. Together, we will continue to innovate and strengthen our life sciences network in the Canton of Fribourg, CH and beyond. 🚀 #CordenPharma #cdmo #innovation #networking #BioAlps #ChambreDeCommerce #AllianceInnovation #Fribourg #Switzerland #promotioneconomiqueducantondefribourg #pharmamanufacturing #pharmaceuticals #drugproducts #tablets
-
+1
-
Join us at CordenPharma, where we drive innovation, shape the future, make a difference in society and help to improve people's life! We strive for excellence, with a network of top talents, to provide the highest quality products for the well-being of patients. Because teamwork is the basis of our success, we are constantly looking for qualified employees to join our team of experts. We foster an atmosphere that embraces everyone’s journey. Encouraging learning, experience, exposure, and respect — a demonstration of our belief that every single effort fuels our collective impact in society. Check out our open opportunities: https://lnkd.in/emEems4z #cordenpharma #cdmo #career #hiring #jobs #recruitment #talentacquisition
-
CordenPharma's Impact on Alzheimer's Disease Medicines Development and Manufacturing Today, we’d like to highlight the remarkable contributions of CordenPharma, a leading CDMO, in the development and production of treatments for Alzheimer’s disease. Through our expert collaboration with pharmaceutical companies, CordenPharma has played a pivotal role in bringing innovative therapies to life, addressing one of the most pressing global health challenges. As a trusted partner in the contract development and manufacturing of Alzheimer’s medicines, CordenPharma's dedication to high-quality standards and efficient production processes has been vital to accelerating the delivery of new treatments. Our specialized expertise in scaling up and optimizing complex Drug Substance and Drug Product manufacturing has enabled pharmaceutical companies to advance promising therapies from lab to commercialization with remarkable efficiency. #CordenPharma #cdmo #WorldAlzheimerDay #purpose #strongertogether
-
Attending CPHI Milan 2024? Visit us at hall 24, booth 24C2 to discover our unique end-to-end CDMO service offerings across six technology platforms to support your complex pharmaceutical modalities and ultimately, the well-being of your patients. Request a meeting with our team by submitting this form: https://lnkd.in/ev38Mey6 Learn more about our: - GLP-1 Peptide Expansion in Europe & the US - LNP GMP Manufacturing Capabilities - Large-scale Terminal & Aseptic Injectable Manufacturing - Specialized Custom & Standard Catalog Lipid Production, including LNP Starter Kits for effective mRNA Formulation - Broad Oral Solid Dose Capacities, including Bioavailability Enhancement, and Oral Peptides - Extensive Small Molecule Capacities We hope to see you soon in Milan! #cordenpharma #cphi #cphimilan #cdmo #pharma #pharmaindustry #pharmaceuticals #drugdevelopment #peptides #glp1 #lipids #lnps #osd #injectables #mRNA